Early reports on ER-β mRNA expression in breast cancer described significant associations with axillary lymph node positivity and rate of tumour recurrence while on endocrine therapy (Speirs et al, 1999a, 1999b), lending credence to the hypothesis that ER-β is a poor prognostic indicator. This evidence concerns the gene ESR2 and neoplasm.